Psychiatr. praxi. 2016;17(3):115

Analýza podskupin neintervenční studie VIVALDI: Agomelatin u dříve neléčených pacientů, v kombinované léčbě a po změně léčby. Int J Psychiatry Clin Pract 2014; 18: 86-96.

doc. MUDr. Jiří Masopust, Ph.D.,
Psychiatrická klinika LF UK a FN Hradec Králové

Laux G, Huttner NA & studijní skupina VIVALDI

Published: October 26, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Masopust J. Analýza podskupin neintervenční studie VIVALDI: Agomelatin u dříve neléčených pacientů, v kombinované léčbě a po změně léčby. Int J Psychiatry Clin Pract 2014; 18: 86-96. Psychiatr. praxi. 2016;17(3):115.
Download citation

References

  1. Laux G; VIVALDI Study Group.The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry 2012; 45: 284-291. Go to original source... Go to PubMed...
  2. Laux G, Huttner NA & VIVALDI study group: Subgroup analysis of the non-interventional study VIVALDI: agomelatine in treatment-na?ve patients, in combination therapy and after treatment switch. Int J Psychiatry Clin Pract 2014; 18: 86-96. Go to original source... Go to PubMed...
  3. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40. Go to original source...
  4. Kim JM, Kim SY, Stewart R, Yoo JA, Bae KY, Jung SW, Lee MS, Yim HW, Jun TY. Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: the CRESCEND study. J Affect Disord. 2011; 129: 183-190. Go to original source... Go to PubMed...
  5. Khoo AL, Zhou HJ, Teng M, Lin L, Zhao YJ, Soh LB, Mok YM, Lim BP, Gwee KP. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants. CNS Drugs 2015; 29: 695-712. Go to original source...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.